Sarcoidosis after Alemtuzumab therapy: Is Alemtuzumab posing a threat to its patients?

Misbah Nizamani · 2024

Read Sarcoidosis after Alemtuzumab therapy: Is Alemtuzumab posing a threat to its patients? by Misbah Nizamani (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11708946.txt.

Description

Misbah Nizamani asked whether a multiple sclerosis drug can trigger sarcoidosis in two thousand twenty-four. Sarcoidosis grows clusters of immune cells in organs. Its cause remains unknown to medicine. Interferon drugs are known to provoke it sometimes. A few patients developed it after alemtuzumab therapy. That antibody strips a marker from immune cells.

It treats relapsing multiple sclerosis and some leukemias. Cases surfaced a few years into treatment. Most patients responded well to sarcoidosis care. Some needed no treatment at all. The pattern raises a caution flag for prescribers. New lung or skin signs deserve a second look. Awareness, not alarm, is the author's message.

Catalog record

CREATORMisbah Nizamani
YEAR2024
COLLECTIONPAPERS
FORMATTXT
FILE SIZE3 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC11708946

Browse the full library · About the Tower of Babel